Is MannKind Corporation (MNKD) a Buy, Sell, or Hold?
NASDAQ : MNKD
MannKind Corporation
$4.13 USD
$0.24 (6.17%)
- Volume
- 9.44M
- Average Volume
- 5.72M
- Market Capitalization
- $1.28B
- P/E Ratio
- -53.43
- Dividend Yield
- 0.00%
- Price Target
- $8.50
- Year High
- $6.51
- Year Low
- $2.23
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.87
Company Overview
NASDAQ
Michael E. Castagna
Biotechnology
Healthcare
MNKD
592
US
USD
Liquidity Metrics
-7.38
1.87
1.50
0.39
0.00
Sales & Valuation
$348.97M
3.54
-21.51
100.33
0.04
Profitability
$0.02
$5.86M
-6.63%
-7.92%
45.59%
-3.21%
P/E Metrics
-53.43
0.30
0.30
Analyst Price Target & Rating
$8.50
$11.00
$6.00
2/5
20 Analysts
-51.41%
Financial Health Scores
-4.37
2/9
$116.6M
$744.4M
$803.6M
$10.53M
Key Metrics (TTM)
$1.66B
4.60
60.24
1.87
45.59%
1.80%
-1.88%
1.00%
168 days
Company Executives
| Name | Title |
|---|---|
| Christopher Prentiss | Chief Financial Officer |
| Stuart A. Tross | Chief People & Workplace Officer |
| Ajay Ahuja | Executive VP & Chief Medical Officer |
| David Thomson | Executive Vice President, General Counsel & Secretary |
| Michael E. Castagna | Chief Executive Officer & Director |
| Dominic Marasco | President of Endocrine Business Unit |
| Sanjay Singh | Executive Vice President of Technical Operations |
Poll Results
No votes yet today — be the first to share your view!
About MannKind Corporation (NASDAQ:MNKD) Stock
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptad ... il), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
MannKind (NASDAQ:MNKD) Shares Gap Up – Still a Buy?
2026-07-26 02:02:49
MannKind Corporation (NASDAQ: MNKD - Get Free Report)'s stock price gapped up prior to trading on Friday. The stock had previously closed at $3.89, but opened at $4.06. MannKind shares last traded at $3.9950, with a volume of 1,925,140 shares traded. Key Stories Impacting MannKind Here are the key news stories impacting MannKind this week:
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
2026-07-24 14:06:27
Mannkind Corporation (NASDAQ:MNKD) shares are trading higher as the company recently announced the U.S. Food and Drug Administration's (FDA) approval of Furoscix ReadyFlow, an at-home treatment option for adults with heart failure or chronic kidney disease.
2026-07-24 12:01:17
MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE
2026-07-24 11:05:35
MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds for the management of fluid overload.
MannKind Announces $50 Million Private Placement
2026-07-24 06:35:00
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
2026-07-24 06:30:00
MannKind announces FDA approval of Furoscix ReadyFlow™, the first & only autoinjector delivering IV-equivalent diuretic therapy for the treatment of edema
What This MannKind Filing Reveals About Three Years of Underperformance
2026-07-20 19:24:19
This MannKind insider filing details the disposition of 46,795 shares. The transaction reduced the insider's direct equity holdings by 9%.
2026-07-20 19:16:02
The transactions involved 76,880 shares with a total value of about $313,000, based on a weighted average execution price of $4.07 per share. The disposition represented 9% of direct common stock holdings, which included shares delivered upon the recent vesting of performance-based awards.
Frequently Asked Questions
-
What is the current MannKind Corporation (MNKD) stock price?
-
MannKind Corporation(NASDAQ:MNKD) stock price is $4.13 in the last trading session. During the trading session, MNKD stock reached the peak price of $6.51 while $2.23 was the lowest point it dropped to. The percentage change in MNKD stock occurred in the recent session was 6.17% while the dollar amount for the price change in MNKD stock was $0.24.
-
MNKD's industry and sector of operation?
-
The NASDAQ listed MNKD is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MNKD?
-
Christopher Prentiss | Chief Financial Officer
Stuart A. Tross | Chief People & Workplace Officer
Ajay Ahuja | Executive VP & Chief Medical Officer
David Thomson | Executive Vice President, General Counsel & Secretary
Michael E. Castagna | Chief Executive Officer & Director -
How many employees does MNKD have?
-
Number of MNKD employees currently stands at 592. MNKD operates from 1 Casper Street, Danbury, CA 91362, US.
-
Link for MNKD official website?
-
Official Website of MNKD is: https://www.mannkindcorp.com
-
How do I contact MNKD?
-
MNKD could be contacted at phone #818 661 5000 and can also be accessed through its website. MNKD operates from 1 Casper Street, Danbury, CA 91362, US.
-
How many shares of MNKD are traded daily?
-
The average number of MNKD shares traded daily for last 3 months was 5.72M.
-
What is the market cap of MNKD currently?
-
The market value of MNKD currently stands at $1.28B with its latest stock price at $4.13